Fed. Circ. Mulls Mixed PTAB Rulings In Teva Antibody IP Fight
A Federal Circuit panel hinted Monday that the Patent Trial and Appeal Board's reasoning might not have been entirely sound in a battle between Teva and Eli Lilly over a mixed bag of board decisions on antibody...To view the full article, register now.
Already a subscriber? Click here to view full article